|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of gastric cancer显示文摘The authors focused on the current surgical treatment of resectable gastric cancer,and significance of periand post-operative chemo or chemoradiation.Gastric cancer is the 4thmost commonly diagnosed cancer and the second leading cause of cancer death worldwide.Surgery remains the only curative therapy,while perioperative and adjuvant chemotherapy,as well as chemoradiation,can improve outcome of resectable gastric cancer with extended lymph node dissection.More than half of radically resected gastric cancer patients relapse locally or with distant metastases,or receive the diagnosis of gastric cancer when tumor is disseminated;therefore,median survival rarely exceeds12 mo,and 5-years survival is less than 10%.Cisplatin and fluoropyrimidine-based chemotherapy,with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients,is the widely used treatment in stageⅣpatients fit for chemotherapy.Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance | Michele Orditura Gennaro Galizia Vincenzo Sforza Valentina Gambardella Alessio Fabozzi Maria Maddalena Laterza Francesca Andreozzi Jole Ventriglia Beatrice Savastano Andrea Mabilia Eva Lieto Fortunato Ciardiello Ferdinando De Vita | 2014 | World Journal of Gastroenterology2014，20，7： | 116 |
| 2 | Clinical management of advanced gastric cancer: The role of new molecular drugs显示文摘Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States.Surgery represents the main approach for this disease but,notwithstanding the advances in surgical techniques,we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates.Despite the development of new drugs has significantly improved the effectiveness of chemothera-py,the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor.Recently,several molecular target agents have been investigated;in particular,trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients.New molecules targeting vascular epithelial growth factor,mammalian target of rapamycin,and anti hepatocyte growth factor-c-Met pathway are also under investigation,with interesting results.Anyway,it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results.In this paper we review the actual'scenario'of targeted treatments,also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma,discussing their efficacy and potential applications in clinical practice. | Ferdinando De Vita Natale Di Martino Alessio Fabozzi Maria Maddalena Laterza Jole Ventriglia Beatrice Savastano Angelica Petrillo Valentina Gambardella Vincenzo Sforza Luigi Marano Annamaria Auricchio Gennaro Galizia Fortunato Ciardiello Michele Orditura | 2014 | World Journal of Gastroenterology2014，20，40： | 12 |
| 3 | Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma:A cohort study显示文摘AIM:To prospectively evaluate the short and long term clinical impact of selective transarterial chemoembolization (TACE) on liver function in patients with hepatocellular carcinoma (HCC).To assess side effects in relation to treatments.To analyze the overall survival and HCC progression free survival probability. METHODS:One hundred and seventeen cirrhotic patients with HCC were enrolled.Baseline liver function included Child-Pugh score and serum levels of alanineaminotransferase (ALT),prothrombin time(PT)and bilirubin.According to Cancer Liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer (BCLC) staging systems,71 patients were eligible for TACE; 32 had previously received treatment for HCC.No significant differences in liver function were observed between previously treated and not treated patients. TACE was performed by selective catheterization of the arteries nourishing the lesions.While hospitalized, patient sunder went clinical,hematologicand ultrasonographic assessments.One month after TACE a CT scan was performed to assess tumor response. A second TACE was performed'on demand'.Liver function tests were checked in all patients every four months.RESULTS:After first TACE,the mean Child-Pugh score increased from a mean baseline 5.62±1.12 to 6.11±1.57 at discharge time (P<0.0001),decreasing after four months to 5.81±0.73 (not significant).ALT,PT and bilirubin significantly (P<0.0001)increased 24 h after TACE and progressively decreased until discharge. After the second TACE,variations in Child-Pugh score,ALT,PT and bilirubin were comparable to that described after the first TACE.No major complications were observed.The mean follow-up was 14.7±6.3 mo (median:16 mo).Only one patient died.No other patient experienced important long term worsening of clinical status.The overall survival probability at twenty-four months was 98.18%with a correspondent HCC progression free survival probability of 69%. CONCLUSION:Selectiv TAC Emayproduce significant,but transitory increases in ALT values, with no major impact on liver function and Child-Pugh score.Preservation of liver function is achievable also in patients previously treated with other therapeutic modalities and in patients undergoing multiple TACE cycles.Liver function can remain stable in the long-term, with optimal medium term survival.This result can be achieved through rigorous patient selection on the basis of tumour characteristics and clinical conditions. | Rodolfo Sacco Marco Bertini Pasquale Petruzzi Michele Bertoni Irene Bargellini Giampaolo Bresci Graziana Federici Luigi Gambardella Salvatore Metrangolo Giuseppe Parisi Antonio Romano Antonio Scaramuzzino Emanuele Tumino Alessandro Silvestri Emanuele Altomare Claudio Vignali Alfonso Capria | 2009 | World Journal of Gastroenterology2009，15，15： | 7 |
| 4 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer显示文摘The prognosis of patients with metastatic colorectal cancer(m CRC) remain poor despite the impressive improvement of treatments observed over the last 20 years that led to an increase in median overall survival from 6 mo, with the only best supportive care, to approximately 30 mo with the introduction of active chemotherapy drugs and targeted agents. The monoclonal antibodies(mo Abs) cetuximab and panitumumab, directed against the epidermal growth factor receptor(EGFR), undoubtedly represent a major step forward in the treatment of m CRC, given the relevant efficacy in terms of progression-free survival, overall survival, response rate, and quality of life observed in several phase Ⅲ clinical trials among different lines of treatment. However, the anti-EGFR mo Abs were shown only to be effective in a subset of patients. For instance, KRAS and NRAS mutations have been identified as biomarkers of resistance to these drugs, improving the selection of patients who might derive a benefit from these treatments. Nevertheless, several other alterations might affect the response to these drugs, and unfortunately, even the responders eventually become resistant by developing secondary(or acquired) resistance in approximately 13-18 mo. Several studies highlighted that the landscape of responsible alterations of both primary and acquired resistance to anti-EGFR drugs biochemically converge into MEK-ERK and PIK3CA-AKT pathways. In this review, we describe the currently known mechanisms of primary and acquired resistance to anti-EGFR mo Abs together with the various strategies evaluated to prevent, overcame or revert them. | Vincenzo Sforza Erika Martinelli Fortunato Ciardiello Valentina Gambardella Stefania Napolitano Giulia Martini Carminia della Corte Claudia Cardone Marianna L Ferrara Alfonso Reginelli Giuseppina Liguori Giulio Belli Teresa Troiani | 2016 | World Journal of Gastroenterology2016，22，28： | 6 |
| 5 | Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity显示文摘 | Luigi E. Adinolfi Michele Gambardella Augusto Andreana Marie-fran?oise Tripodi Riccardo Utili Giuseppe Ruggiero | 2001 | Hepatology2001，，6： | 4 |
| 6 | 创业决策的科学方法及其在中国的推广显示文摘创业决策的科学方法包括清晰地提出问题、开发关于行为影响的理论,以及使用现有数据或从定义明确的实验设计中获取的数据来检验理论。其运作机制能够有效地形成、检验和更新创业者对创业想法价值的信念,对创业想法终止、转向(pivoting)和创业绩效具有重要影响。本文综合理论、经验和实践导向的新兴文献,概括了科学决策方法的发展情况。最后,本文讨论了将科学方法推广到中国创业环境的益处和挑战。 | Arnaldo Camuffo Yanhong Ding(校订) Alfonso Gambardella 罗银燕(翻译) 林道谧(校订) | 2022 | 管理学季刊2022，7，4： | 3 |
| 7 | Ant Algorithms for Discrete Optimization显示文摘 | Dorigo M Caro G D Gambardella L M | 1999 | Artificial Life1999，5，3： | 2 |
| 8 | Ant colony system:a cooperative learning approach to the traveling salesman problem显示文摘 | Dorigo M Gambardella L.M | | 0，，： | 2 |
| 9 | Ant Colony System: a Cooperative Learning Approach to the Traveling Salesman Problem 显示文摘 | Dorigo M Gambardella L M | 1997 | IEEE Transactions on Evolutionary Computation1997，1，1： | 2 |
| 10 | Ant Colornies for the Quadratic Assignment Problem显示文摘 | Gambardella L M Taillard E D Dorigo M | 1999 | Journal of the Operational Research Society1999，50，： | 2 |
| 11 | Ant Colony System:A Cooperative Learning Approach to the Traveling Salesman Problem显示文摘 | Dorigo M Gambardella L M | | 0，，： | 2 |
| 12 | Ant algorithms for discrete optimization显示文摘 | Macro Dorigo Gianni Di Caro Luca M Gambardella | 1999 | Artificial Life1999，5，3： | 2 |
| 13 | Ant colonies for the traveling salesman problem显示文摘 | Dorigo M Gambardella L M | 1997 | Biosystems1997，43，2： | 2 |
| 14 | Ant algorithms for discrete optimization显示文摘 | Dorigo M Di Caro G Gambardella L M | 1999 | Artificial Life1999，5，： | 2 |
| 15 | Ant colony system: a cooperative learning approach to the traveling salesman problem 显示文摘 | Dorigo M Gambardella L M | 1997 | IEEE Transactions on Evolutionary Computation1997，，1： | 1 |
| 16 | Ant colony systcm:A cooperative learning approach to the traveling salesman prohlem显示文摘 | Dorigo M Gambardella L M | 1997 | IEEE Transaetions on Evolutionary Computation1997，1，1： | 1 |
| 17 | Ant Colonies for the Travelling sales-man Problem 显示文摘 | Marco Dorigo Luca Maria Gambardella | 1997 | BioSystems1997，，43： | 1 |
| 18 | Ant colony system:a cooperative learning approach to the traveling salesman problem显示文摘 | Dorigo M Gambardella L M | 1997 | IEEE Trans on Evolutionary Computation1997，1，1： | 1 |
| 19 | Ant Algorithms for Discrete Optimization 显示文摘 | Dorige M Caro G D Gambardella L M | 1999 | Artificial Life1999，5，3： | 1 |
| 20 | Ant algorithms for discrete optimization显示文摘 | Dorigo M Caro G D Gambardella L M | 1999 | Artificial Life1999，5，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员